Specific clinical and radiological features may identify risk for leptomeningeal dissemination in oligodendroglioma
Risk Markers Linked to Spread of Oligodendroglioma in Spinal Fluid
This scoping review of 15 studies identifies several indicators associated with leptomeningeal dissemination (LMD) in patients with oligoden…
Identifying specific markers like high Ki-67 levels and ventricular involvement may help doctors track the spread of certain brain tumors.
HOX gene dysregulation influences cellular processes but currently lacks utility as reliable HNSCC biomarkers
HOX genes play complex roles in head and neck cancer
This mini-review examines the role of HOX genes in head and neck squamous cell carcinoma (HNSCC). The authors conclude that while these gene…
New research highlights how HOX genes drive tumor growth and survival in head and neck cancers, though their use as clinical tools is still …
FDA Approves Alecensa (alectinib) for Adjuvant Treatment of ALK-Positive NSCLC
FDA approves Alecensa for early lung cancer after surgery to reduce recurrence risk.
The FDA approved Alecensa (alectinib) for adjuvant treatment of ALK-positive NSCLC after tumor resection in patients with tumors ≥4 cm or no…
The FDA approved Alecensa (alectinib) for patients with ALK-positive non-small cell lung cancer after surgery, if the tumor was large or had…
FDA Approves Yervoy (ipilimumab) for Multiple Indications Including Melanoma and Lung Cancer
FDA approves Yervoy for several advanced cancers including melanoma and lung cancer.
The FDA approved Yervoy (ipilimumab) for unresectable or metastatic melanoma, adjuvant melanoma, advanced renal cell carcinoma, MSI-H/dMMR c…
The FDA has approved Yervoy (ipilimumab) for many advanced cancers, including melanoma, lung, kidney, and colon cancers. It is used alone or…
Sacubitril/Valsartan preserves left ventricular systolic function and attenuates GLS deterioration during chemotherapy
Sacubitril and Valsartan May Protect Heart Function During Chemotherapy
This meta-analysis of randomized controlled trials evaluates sacubitril/valsartan for patients undergoing chemotherapy to manage chemotherap…
A new review suggests the medication sacubitril/valsartan may help preserve heart muscle function for patients undergoing chemotherapy.
Comprehensive palliative care improves quality of life, survival, and symptoms in thoracic cancer patients
Palliative care improves quality of life for thoracic cancer patients
This meta-analysis of 6490 people with thoracic cancer found that comprehensive palliative care interventions improved quality of life (SMD …
Comprehensive palliative care can improve survival, manage symptoms, and boost quality of life for people living with thoracic cancers.
MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate Accuracy
MRI Radiomics Help Predict TERTp Mutation in Glioma Patients
Meta-analysis of 14 studies shows MRI radiomics predicts TERTp mutation in glioma with AUC 0.79; combined models improve accuracy to 0.82.
New analysis shows MRI-based radiomics can help predict specific genetic mutations in glioma, potentially aiding early diagnosis and treatme…
Cisplatin-based chemotherapy associated with superior survival over carboplatin in advanced bladder cancer
Cisplatin shows better survival for patients with bladder cancer
This meta-analysis of 2543 patients found that cisplatin-based regimens are associated with significantly better overall survival and cancer…
New data reveals that cisplatin-based chemotherapy leads to longer survival than carboplatin for many people with advanced bladder cancer.
DaVinci Single-Port transoral robotic surgery is feasible across multiple indications including oncology and sleep apnea
Single-Port Robot Shows Promise for Sleep Apnea Surgery
This systematic review and meta-analysis of 479 patients evaluates the feasibility of DaVinci Single-Port (SP) transoral robotic surgery (TO…
A new analysis finds single-port robotic surgery for sleep apnea is feasible, with short operating times and low blood loss.
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
FDA Approves Voranigo (vorasidenib) for IDH-Mutant Grade 2 Glioma
FDA approves new targeted drug Voranigo for certain brain tumors.
FDA approved Voranigo (vorasidenib) for adult and pediatric patients 12+ with Grade 2 astrocytoma or oligodendroglioma harboring IDH1/2 muta…
The FDA approved Voranigo (vorasidenib) for adults and children 12+ with Grade 2 astrocytoma or oligodendroglioma that have an IDH1 or IDH2 …
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer
Trial shows omitting carboplatin maintains success in breast cancer
This Phase III randomized controlled trial of 766 women with untreated, stage II and III, HER2-positive invasive breast cancer found that th…
A new clinical trial shows that removing one specific drug can lower severe side effects while maintaining high success rates for certain br…